Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
A1 A2 A3 A4
INCY
FY2025 Q4
Улучшается
Отчётный звонок Incyte Corporation
Вывод Buzzberg
Core business ex-Jakafi expected to grow over 30% in 2026
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
Вывод Buzzberg Core business ex-Jakafi expected to grow over 30% in 2026 Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance. Читать полный анализСвернуть анализ
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
- Core business (ex-Jakafi) is guided to grow ~30% in 2026, driven by strong uptake of Monjuvi, Nictimbo, and Opsalura.
- Four key product launches are anticipated in late 2026/early 2027: Jakafi XR, Monjuvi in frontline DLBCL, Povacitinib for HS, and Opsalura for HS.
- Povacitinib NDA accepted, targeting large pre-biologic HS population as first oral treatment.
HEM_ONC Выручка$0.583BФакт
JAKAFI Выручка$3.093BФакт
OPSALURA Выручка$0.678BФакт
PRODUCT_SALES Выручка$4.35BФакт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Pipeline
Jakafi XR approval and launch expected mid-2026
Regulatory
Povacitinib NDA submitted for HS, filing acceptance this quarter
Показать ещё 3 тезиса
Clinical Data
FrontMIND trial met primary endpoint PFS in first-line DLBCL
Pipeline
Opluura PN development paused after FDA feedback
Guidance
Management expects four product approvals in late 2026 and early 2027
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| HEM_ONC Выручка | $0.583B | Факт |
| JAKAFI Выручка | $3.093B | Факт |
| OPSALURA Выручка | $0.678B | Факт |
| PRODUCT_SALES Выручка | $4.35B | Факт |
| Выручка | $1.5068B | Факт |
| EPS | $1.80 | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Операционная маржаRD_SGA | FY2026 | $3.495B–$3.675B | $3.585B | Подтверждён |
| Выручка | FY2026 | $4.77B–$4.94B | $4.855B | Подтверждён |
| ВыручкаJAKAFI | FY2026 | $3.22B–$3.27B | $3.245B | Подтверждён |
| ВыручкаOPSALURA | FY2026 | $0.75B–$0.79B | $0.77B | Подтверждён |
| ВыручкаHEM_ONC | FY2026 | $0.8B–$0.88B | $0.84B | Подтверждён |
| ВыручкаCORE_EX_JACKIFY | FY2026 | $1.57B–$1.69B | $1.63B | Подтверждён |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed strong confidence in the pipeline and growth trajectory, emphasizing multiple catalysts and a clear path to replace Jakafi.
Внешние сигналы
Альфа цепочки поставок · 4с момента звонка
Incyte is executing a deliberate transition: expecting 4 product launches in late 2026/early 2027 (Jakafi XR, Monjuvi frontline DLBCL, Povacitinib HS, Opsalura), with the core business (ex-Jakafi) guided to ~30% growth in 2026.
Доказательства
“Sales for our core business, X-Jackify, will range between $1.57 and $1.69 billion, representing roughly a 30% growth rate at the midpoint in 2026.”
Formulary negotiations for future Jakafi XR are in progress, with management expecting enough coverage to enable a 10-30% conversion rate from the IR version, contributing minimal revenue in 2026 but significant potential by 2029.
Доказательства
“With an extended release formulation like Jackify, you're probably not going to reach into that top tier of formulary coverage. But we should get enough formulary coverage to enable a conversion rate of 10% to 30%.”
Incyte’s KRAS G12D (734) and TGF-betaR2xPD-1 (A9O) programs target 'wide open white spaces' in pancreatic and MSS colorectal cancer, aiming to be first or early to market with potential for significant market share.
Доказательства
“These are, these are the largest wide open white spaces in cancer. We could be first or early in pancreatic and we could be first and only in colorectal.”
Povacitinib’s opportunity is to capture the 75% of HS patients not on advanced systemics, focusing on the pre-biologic population currently cycling through antibiotics/steroids.
Доказательства
“There's 150,000 people using products that are not approved for HS, antibiotics, and steroids. Our ability to drive sales of povocitinib is to get to that group...”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 0. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.